Overall Survival Analysis of First Line CDK4/6 Inhibitors in a Large Real-World Cohort of Patients with Hormone Receptor-Positive (Hr+)/her2-Negative Metastatic Breast Cancer.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要